Member Info for Palmsairport

A watched pot never boils. ..

On Boots, I note the purchases are around 22 (this morning at 11.30) and much more by the end of the day and so the sales are clearly sustained (in addition to direct sales and Lloyds), as was predicted by MHC. Still ultimately, it's all coming down to the introduction of the new products and the success of the launch; that will be the real turning-point for the re-rate.

Well said Novice Hunter: that brilliantly summarised and so very true for this and so many other shares. Suddenly: the rise begins and your lamenting: why didn't I hold on or why didn't I buy more when it was so low. There are fundamentals; technicals; and then there is the psychology of it all.

Shares tumble as Russia-Ukraine tensions rattle markets
https://www.bbc.co.uk/news/business-60117433

https://www.reuters.com/markets/europe/global-markets-wrapup-1-pix-2022-01-24/
Shares shudder at potential Ukraine conflict

This is great news smudge. The revenue from the Covid testing has provided the foundations for the new products. Hopefully, more good news to come following their launch.

Some interesting discussions this morning as we all await the bigger prize. It would be great to hear Rktech's views on the recent placing and its implications, but also today's news.

Although we await the latest update, looking ahead, we were informed that 'Full year results to meet or exceed higher end of expectation range'.

A belated happy new year to everyone. In the December RNS it was stated that forecasts were looking positive especially if there are 'no material changes to COVID restrictions imposed by the UK Government over the next two weeks, which might significantly impact the ability for passengers to travel in or out of the UK' . In actual fact there was no change until the 10th of January and so this should be viewed as a big bonus. When the in-bound PCR testing was dropped last year in September, the company made it clear that they still expected good levels of income from the outbound testing and that has remained the case since then. We now have the LFTs testing and also a contract with Lloyds and so on the Covid testing front the company's position is consolidated. Building on the upcoming trading update (mid-Jan), if the new products are successfully introduced in Q1, then the sort of issues with been having with the deflated share price should be well behind us. That's my take on things.

Immensa, which was only established in May 2020, has been awarded almost £170m of taxpayer’s money for Covid testing contracts throughout the pandemic.

Immensa lab closed one month after ‘unusual’ Covid results first detected
Estimated 43,000 incorrect false negatives were sent out to the public from the lab in Wolverhampton.
Disgraceful!

Testing is going to be here for a while:
https://www.independent.co.uk/life-style/health-and-families/covid-pandemic-end-omicron-delta-lockdown-b1978180.html
and the services of reliable companies

Things should come good for MHC in 2022. They are professional and focused on the task ahead.

This is quite shocking. Will it fall any lower?

A pre-arrival negative test and then another PCR test after arrival - remain in place for all travellers

https://www.bbc.co.uk/news/live/uk-59646151

My apologies pensioner59. That was a bit silly of me, sorry. Still, it all suggests that, on a number of fronts, quite a bit of activity is going on. Ironically, we made headlines in what is described as the 'THE UK'S NATIONAL B2B MEDIA COMPANY' https://www.insidermedia.com/news/wales/myhealthchecked-hails-extraordinary-progress

Hi Pensioner59, from a cursory search, I came across this: 'B2B marketing refers to a market where businesses are the purchasers of goods and services from other businesses'.

I note in the RNS that it mentions 'high levels of demand for the recently reinstated PCR Day-2 test kits and associated laboratory services'. Is this provision of laboratory services separate work that is carried out on behalf of other agencies or firms? Also, great to hear that the Covid testing has 'provided us with a strong base from which to develop our extended product pipeline ready for commercialisation next year'. This is where the focus needs to be if we want a serious re-rate.

That's very impressive Dactions and this is something pensioner59 pointed out a week or so ago: not everyone is taking the time to fill out the reviews and so in fact they represent only a small proportion of the actual sales of the testing kits. Surely, the updated figures, whenever we get them, are going to be the game changer in terms of an improved sustained price action.

Hi Dactions
Re: 'they are continuing to work intensely on tests'
I was just wondering do you mean developing the new tests and products? Or the Covid ones?

Thanks,

Yes that's the reality JiffyBag. As they say 'Hindsight is a beautiful thing'.
As far as the long term prospects for GST are concerned, the vision and expertise of the board and the products they have developed suggest that there are great things to which we can look forward here.